Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC -- Ignore unavailable to you. Want to Upgrade?

To: Joseph A. Aboaf who wrote (1847)	5/17/1999 9:04:00 PM
From: Area51	Respond to of 2028

If you read the referenced URL, Genentech got a court verdict saying that Biotropin (BTGC hGH drug) violated their patent. Therefore BTGC was/is not allowed to import Biotropin into the US. What happens if Genentech loses? Thats what I'd like to know also. It's not clear to me that BTGC will benefit. I would think that the Genentech patent remains valid but really belongs to Genentech and UCSF jointly. The only way that BTGC would benefit is if Genentech make material false statements during the Genentech\BTGC trial and thereby damaged BTGC (in which case BTGC could probably sue for triple damages). But this is my opinion only and I don't claim to be a patent attorney.